Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532311 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 411
- Enrollment target
NCT00532311 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 411 participants.
The verdict
NCT00532311, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 411 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with statins on cholesterol levels in subjects with hypercholesterolemia
Interventions
- DRUG Lapaquistat acetate and stable statin therapy
- DRUG Stable statin therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532311
The ClinicalTrials.gov registry entry for NCT00532311 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lapaquistat acetate and stable statin therapy is the first listed.
NCT00532311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532311 about?
NCT00532311 is a clinical study titled "Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia". The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with statins on cholesterol levels in subjects with hypercholesterolemia
What is the current status of trial NCT00532311?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 411 participants. The study started on 2007-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00532311?
The interventions under investigation include: Lapaquistat acetate and stable statin therapy (DRUG), Stable statin therapy (DRUG).
Who is sponsoring clinical trial NCT00532311?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.